Riboflavin 5'-Phosphate

Riboflavin 5'-Phosphate

SCHEMBL297863

Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@H](O)COP(=O)(O)O)c2cc1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 1.00
NR3C1 P04150 1/20 1.00
ADRB2 P07550 1/20 1.00
HTR2C P28335 1/20 1.00
ADRA1A P35348 1/20 1.00
PTGS2 P35354 1/20 1.00
TST Q16762 2/20 0.83
HSPD1 P10809 1/20 0.83
HSPE1 P61604 1/20 0.83
MEN1 O00255 7/20 0.74
KMT2A Q03164 7/20 0.74
USP2 O75604 4/20 0.74
HTT P42858 4/20 0.74
HAT1 O14929 4/20 0.74
RBBP7 Q16576 4/20 0.74
KDM4E B2RXH2 3/20 0.74
RECQL P46063 3/20 0.74
CASP7 P55210 3/20 0.74
MAPT P10636 3/20 0.74
CASP1 P29466 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Riboflavin 5'-Phosphate SCHEMBL190079 1.00 ESR1 (1.00) ESR1NR3C1ADRB2HTR2CADRA1A
Riboflavin 5'-Phosphate SCHEMBL41133 1.00 ESR1 (1.00) ESR1NR3C1ADRB2HTR2CADRA1A
Riboflavin 5'-Phosphate SCHEMBL1532396 1.00 ESR1 (1.00) ESR1NR3C1ADRB2HTR2CADRA1A
Riboflavin 5'-Phosphate SCHEMBL6681480 0.99 ESR1 (0.98) ESR1NR3C1ADRB2HTR2CADRA1A
Riboflavin 5'-Phosphate SCHEMBL29592831 0.96 ESR1 (0.93) ESR1NR3C1ADRB2HTR2CADRA1A
SCHEMBL14571231 0.94 ESR1 (0.89) ESR1NR3C1ADRB2HTR2CADRA1A
SCHEMBL19864293 0.94 ESR1 (0.88) ESR1NR3C1ADRB2HTR2CADRA1A
SCHEMBL11995383 0.94 ESR1 (0.88) ESR1NR3C1ADRB2HTR2CADRA1A
SCHEMBL3402467 0.93 ESR1 (0.86) ESR1NR3C1ADRB2HTR2CADRA1A
Riboflavin 5'-Phosphate SCHEMBL8656633 0.92 TST (0.98) ESR1NR3C1ADRB2HTR2CADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116120585-B Preparation method for preparing amino acid photocatalytic decarboxylation oxidation product by means of photocatalyst 北京化工大学 2023-11-14 CN claimed
CN-116120585-A Preparation method for preparing amino acid photocatalytic decarboxylation oxidation product by means of photocatalyst 北京化工大学 2023-05-16 CN claimed
EP-2179006-B1 INORGANIC-ORGANIC COMPOSITE FLUORESCENT SUBSTANCE KARLSRUHER INST TECHNOLOGIE (DE) 2020-07-01 EP claimed
US-8480928-B2 Inorganic-organic composite luminophore KARLSRUHER INSTITUT FUR TECHNOLOGIE (KIT) (DE) 2013-07-09 US claimed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 EP claimed
WO-2011132171-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 WO claimed
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 US claimed
US-20110198538-A1 INORGANIC-ORGANIC COMPOSITE LUMINOPHORE Karlsruher Institut for Technologie (KIT) (DE) 2011-08-18 US claimed
US-7776364-B2 Non-surgical method for treating cataracts in mammals including man ADVANCED SCIENTIFIC, LLC (US) 2010-08-17 US claimed
US-20070224294-A1 Novel non-surgical method for treating cataracts in mammals including man ADVANCED SCIENTIFIC 2007-09-27 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-12515213-B2 Membranes and their uses FUJIFILM MANUFACTURING EUROPE B.V. (NL) 2026-01-06 US disclosed
EP-4615577-A1 METHODS OF TREATING EYE PAIN AND EYE DISORDERS Aisa Pharma, Inc. (US) 2025-09-17 EP disclosed
EP-3441049-B1 OPHTHALMIC TREATMENT DEVICE EPION THERAPEUTICS INC (US) 2025-08-20 EP disclosed
EP-4558546-A1 PHOTOCURABLE HYDROGEL COMPOSITIONS Tympanogen, Inc. (US) 2025-05-28 EP disclosed
US-4668630-A COMPLEXING LACTIC DEHYDROGENASE WITH DIPOTASSIUM OXALATE BECKMAN INSTRUMENTS, INC. (US) 1987-05-26 US disclosed
EP-0027631-B1 FLAVIN ADENINE DINUCLEOTIDE-LABELED PROTEIN AND POLYPEPTIDE CONJUGATES MILES LABORATORIES, INC. (US) 1982-05-05 EP disclosed
EP-0027631-A1 Flavin adenine dinucleotide-labeled protein and polypeptide conjugates MILES LABORATORIES, INC. (US) 1981-04-29 EP disclosed
US-4259232-A IMMUNOASSAY REAGENTS MILES LABORATORIES, INC. (US) 1981-03-31 US disclosed
US-4255566-A N6-(OMEGA-AMINOALKYL)ADENINE DINUCLEOTIDE DERIVATIVES; IMMUNOASSAY MILES LABORATORIES (US) 1981-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents NOS2, NOS1, NOS3 ESR1 1694/4885NR3C1 1961/4885ADRB2 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.